The number of cancer stem cells in the tumor tissue and perifocal tissue of non-muscle invasive bladder cancer

L. I. Belyakova, A. N. Shevchenko, A. B. Sagakyants, E. Bondarenko, O. G. Shulgina, E. Ulyanova, E. V. Filatova, I. A. Khomutenko
{"title":"The number of cancer stem cells in the tumor tissue and perifocal tissue of non-muscle invasive bladder cancer","authors":"L. I. Belyakova, A. N. Shevchenko, A. B. Sagakyants, E. Bondarenko, O. G. Shulgina, E. Ulyanova, E. V. Filatova, I. A. Khomutenko","doi":"10.37748/2686-9039-2022-3-1-1","DOIUrl":null,"url":null,"abstract":"Purpose of the study. Determine the content of cancer stem cells (CSCs) in the tumor tissue (TT) and perifocal tissues (PT) in muscle-non-invasive bladder cancer.Materials and methods. We’ve examined fragments of TT and PT of 7 muscle-non-invasive bladder cancer (NMIBC) after surgical intervention – transurethral resection of the urinary bladder (TUR). In tissue samples that were used to obtain cell suspension of TT and PT using the BD Medimachine apparatus (BD, USA) was treated with monoclonal antibodies CD45-APCCy7, CD44-FITC, CD133-РЕ, CD24-PE (BD, USA) and were assessed on flow cytometer FacsCantoII (BD, USA). The percentage of cells with CSC phenotypic markers was determined in the analysis sample: CD45-CD44+CD24+, CD45-CD44+, CD45-CD24+, CD45-CD133+, CD45-CD44+CD133+. The presence of significant differences in the groups was evaluated using the STATISTICA 13 software package and the differences between the samples were considered significant at p < 0.05. The percentage of cells of the corresponding phenotype was calculated relative to the total number of cells. The percentage of cells with the corresponding phenotype was calculated relative to the total number of cells.Results. The relative numbers of cells with CSC phenotypic markers, such as CD24, CD44, were 77 % and 58 % higher in TT than in PT: 18.3 ± 3.5 vs. 4.3 ± 2.1, p ≤ 0.044 and 15.5 ± 5.3 vs. 6.5 ± 0.8, p ≤ 0.043, respectively. The number of CD133+ cells was 83 % higher in PT compared to TT – 41.6 ± 12.1 vs. 22.7 ± 7.6, p ≤ 0.047.Conclusion. The study of CSCs is a promising direction for the study of oncogenesis and can be used to assess the nature of the further development of relapse and / or progression of the disease, as well as various therapeutic approaches that are aimed at eliminating with CSC phenotypic markers and blocking the pathways leading to the emergence and maintenance of this cell population in patients with NMIBC.","PeriodicalId":22147,"journal":{"name":"South Russian Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Russian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37748/2686-9039-2022-3-1-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Purpose of the study. Determine the content of cancer stem cells (CSCs) in the tumor tissue (TT) and perifocal tissues (PT) in muscle-non-invasive bladder cancer.Materials and methods. We’ve examined fragments of TT and PT of 7 muscle-non-invasive bladder cancer (NMIBC) after surgical intervention – transurethral resection of the urinary bladder (TUR). In tissue samples that were used to obtain cell suspension of TT and PT using the BD Medimachine apparatus (BD, USA) was treated with monoclonal antibodies CD45-APCCy7, CD44-FITC, CD133-РЕ, CD24-PE (BD, USA) and were assessed on flow cytometer FacsCantoII (BD, USA). The percentage of cells with CSC phenotypic markers was determined in the analysis sample: CD45-CD44+CD24+, CD45-CD44+, CD45-CD24+, CD45-CD133+, CD45-CD44+CD133+. The presence of significant differences in the groups was evaluated using the STATISTICA 13 software package and the differences between the samples were considered significant at p < 0.05. The percentage of cells of the corresponding phenotype was calculated relative to the total number of cells. The percentage of cells with the corresponding phenotype was calculated relative to the total number of cells.Results. The relative numbers of cells with CSC phenotypic markers, such as CD24, CD44, were 77 % and 58 % higher in TT than in PT: 18.3 ± 3.5 vs. 4.3 ± 2.1, p ≤ 0.044 and 15.5 ± 5.3 vs. 6.5 ± 0.8, p ≤ 0.043, respectively. The number of CD133+ cells was 83 % higher in PT compared to TT – 41.6 ± 12.1 vs. 22.7 ± 7.6, p ≤ 0.047.Conclusion. The study of CSCs is a promising direction for the study of oncogenesis and can be used to assess the nature of the further development of relapse and / or progression of the disease, as well as various therapeutic approaches that are aimed at eliminating with CSC phenotypic markers and blocking the pathways leading to the emergence and maintenance of this cell population in patients with NMIBC.
非肌肉浸润性膀胱癌肿瘤组织及局灶周围组织中肿瘤干细胞的数量
研究目的:测定肌肉非侵袭性膀胱癌肿瘤组织(TT)和局点周围组织(PT)中肿瘤干细胞(CSCs)的含量。材料和方法。我们检查了7例肌肉性非侵袭性膀胱癌(NMIBC)经尿道膀胱切除术(TUR)后的TT和PT片段。在使用BD Medimachine设备(BD,美国)获得TT和PT细胞悬液的组织样本中,用单克隆抗体CD45-APCCy7, CD44-FITC, CD133-РЕ, CD24-PE (BD,美国)处理,并在流式细胞仪FacsCantoII (BD,美国)上进行评估。分析样本中具有CSC表型标记的细胞百分比:CD45-CD44+CD24+、CD45-CD44+、CD45-CD24+、CD45-CD133+、CD45-CD44+CD133+。使用STATISTICA 13软件包评估组间是否存在显著差异,p < 0.05为样本间差异显著。计算相应表型的细胞相对于细胞总数的百分比。计算具有相应表型的细胞相对于细胞总数的百分比。TT组CSC表型标记CD24、CD44细胞的相对数量分别比PT组高77%和58%:分别为18.3±3.5 vs. 4.3±2.1 (p≤0.044)和15.5±5.3 vs. 6.5±0.8 (p≤0.043)。PT组CD133+细胞数比TT组(41.6±12.1比22.7±7.6)高83%,p≤0.047。对CSC的研究是肿瘤发生研究的一个有希望的方向,可用于评估疾病复发和/或进展的进一步发展的性质,以及旨在消除CSC表型标记和阻断导致NMIBC患者中该细胞群出现和维持的途径的各种治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信